Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults

PHASE1CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

Not specified

Study Completion Date

August 31, 1999

Conditions

HIV Infections

Interventions

BIOLOGICAL

ALVAC(2)120(B,MN)GNP (vCP1452)

BIOLOGICAL

gp160 MN/LAI-2

BIOLOGICAL

ALVAC(1)120(B,MN)GNP (vCP1433)

BIOLOGICAL

ALVAC-HIV MN120TMG (vCP205)

BIOLOGICAL

ALVAC-RG Rabies Glycoprotein (vCP65)

Trial Locations (6)

Univ. of Rochester AVEG, Rochester

JHU AVEG, Baltimore

UAB AVEG, Birmingham

Vanderbilt Univ. Hosp. AVEG, Nashville

St. Louis Univ. School of Medicine AVEG, St Louis

UW - Seattle AVEG, Seattle

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00000904 - Safety and Effectiveness of Anti-HIV Vaccines in HIV-Negative Adults | Biotech Hunter | Biotech Hunter